Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000010159
- Lead Sponsor
- akakinen Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1-Type 1 Diabetes Mellitus 2-Previous treatment with other incretin mimetics within the previous three months before screening. 3-Insulin-requiring type 2 Diabetes Mellitus 4-Impaired hepatic function, measured as serum glutamic oxaloacetic transaminase [sGOT ( Aspartate Aminotransferase , ASAT)] or serum glutamic pyruvic transaminase (sGPT) ≥ 100 IU/L 5-Unstable cardiovascular or cerebrovascular disease. 6-Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. 7-Female of childbearing potential who are not using adequate contraceptive menthods 8-Known or suspected allergy to trial medication(s), excipients, or related products. 9-Any contraindications to liraglutide.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma glucose profile (CGM) on-haemodialysis and off-haemodialysis
- Secondary Outcome Measures
Name Time Method Plasma liragutide levels while on-haemodialysis and off-haemodialysis